DNA Modification Methylases
-
Subject Areas on Research
- A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.
- A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors.
- A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
- A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.
- Association and interactions between DNA repair gene polymorphisms and adult glioma.
- Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
- Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying).
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
- DNA methyltransferase levels and altered CpG methylation in the total genome and in the GSTP1 gene in human glioma cells transfected with sense and antisense DNA methyltransferase cDNA.
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
- Genetic variants in MGMT and risk of lung cancer in Southeastern Chinese: a haplotype-based analysis.
- Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF).
- Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
- Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.
- Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
- MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.
- MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy.
- MGMT: Immunohistochemical Detection in High-Grade Astrocytomas.
- Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.
- O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
- Plasticity of renal erythropoietin-producing cells governs fibrosis.
- Polymorphisms of the DNA repair gene MGMT and risk and progression of head and neck cancer.
- Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.
- SOS induction as an in vivo assay of enzyme-DNA interactions.
- Single substitution in H3.3G34 alters DNMT3A recruitment to cause progressive neurodegeneration.
- Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O6-methylguanine-DNA methyltransferase.
- Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
- Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma.
- Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.
- The biological significance of substrate inhibition: a mechanism with diverse functions.
- Twenty-year survival in glioblastoma: a case report and molecular profile.
- Use of integrative epigenetic and cytogenetic analyses to identify novel tumor-suppressor genes in malignant melanoma.
- Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma.
-
Keywords of People
- McLendon, Roger Edwin, Professor of Pathology, Pathology
- Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering